Alcon announces BRYTLY approval as Alcon stock trades at EUR 58.83
Published on 10/18/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA approval and upcoming session
- Alcon announced FDA approval for BRYTLY on October 16, 2026, with effects lasting up to 12 hours.
- Alcon stock trades in weekend trading at Lang & Schwarz at EUR 58.83 at 5:43 p.m. CEST on October 18, 2026.
- The next Xetra session is scheduled for October 19, 2026.
Alcon announced on October 16, 2026, that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, while Alcon stock trades at EUR 58.83 in weekend trading at Lang & Schwarz at 5:43 p.m. CEST on October 18, 2026. The approval was reported in an Alcon release distributed by Business Wire.
Market context: Market report SMI.
The week in figures
Alcon stock was quoted at EUR 58.83 at Lang & Schwarz at 5:43 p.m. CEST on October 18, 2026. The quote is a weekend-trading indication for investors in Germany.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CEST is shown by the continuously updated real-time quote of Alcon stock.
Chronology of the week
On October 16, 2026, Alcon announced that the FDA had approved BRYTLY. The company said one drop works in one minute and delivers up to 12 hours of whiter, brighter-looking eyes. Alcon also said BRYTLY lasts up to 50% longer than Lumify. The product is expected to be available at major retailers and online in the coming months, according to the Business Wire release.
Dates of the coming week
The next Xetra session is scheduled for October 19, 2026. The BRYTLY release did not provide a specific retail launch date and referred to availability in the coming months.
